Idelalisib+Obinutuzumab in Patients With Relapsed/Refractory Follicular Lymphoma
- First Posted Date
- 2019-03-26
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Fondazione Italiana Linfomi - ETS
- Target Recruit Count
- 5
- Registration Number
- NCT03890289
- Locations
- 🇮🇹
Azienda Ospedaliera Universitaria Careggi - Unità funzionale di Ematologia, Firenze, Italy
🇮🇹AOU Maggiore della Carità di Novara - SCDU Ematologia, Novara, Italy
🇮🇹Azienda sanitaria-universitaria integrata Trieste (ASUITS) - SC Ematologia, Trieste, Italy
Ibrutinib + R-CHOP Followed by Ibrutinib Maintenance
- First Posted Date
- 2018-11-06
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Fondazione Italiana Linfomi - ETS
- Target Recruit Count
- 75
- Registration Number
- NCT03731234
- Locations
- 🇮🇹
Ospedale di Castelfranco Veneto - Oncoematologia IOV, Castelfranco Veneto, Treviso, Italy
🇮🇹A.O. SS. Antonio e Biagio e Cesare Arrigo - S.C. Ematologia, Alessandria, Italy
🇮🇹Università Politecnica delle Marche- Clinica di Ematologia, Ancona, Italy
Rituximab, Bendamustine and Cytarabine Followed by Venetoclax in High Risk Elderly Patients With MCL
- First Posted Date
- 2018-06-26
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Fondazione Italiana Linfomi - ETS
- Target Recruit Count
- 141
- Registration Number
- NCT03567876
- Locations
- 🇮🇹
Grande Ospedale Metropolitano Bianchi Melacrino Morelli, Ematologia, Reggio Calabria, Italy
🇮🇹IRCCS Istituto Tumori Giovanni Paolo II, UOC Ematologia, Bari, Italy
🇮🇹ASST Spedali Civili, Ematologia, Brescia, Italy
Use of Venetoclax as Single Agent in Patients With Relapsed/Refractory BCL-2 Positive Peripheral T Cell Lymphoma
- Conditions
- T-Cell Lymphoma RefractoryT-Cell Lymphoma Relapsed
- Interventions
- First Posted Date
- 2018-06-12
- Last Posted Date
- 2023-12-12
- Lead Sponsor
- Fondazione Italiana Linfomi - ETS
- Target Recruit Count
- 22
- Registration Number
- NCT03552692
- Locations
- 🇮🇹
Azienda Sanitaria Universitaria Integrata di Udine (A.S.U.I. Udine) - SOC Clinica Ematologica, Udine, Italy
🇮🇹Centro Riferimento Oncologico - S.O.C. Oncologia Medica A, Aviano, Italy
🇮🇹ASST Spedali Civili di Brescia - Ematologia, Brescia, Italy
Study for Elderly (≥ 65 Years) Patients With Classical Hodgkin Lymphoma Undergoing CGA at Diagnosis
- Conditions
- Classical Hodgkin Lymphoma
- Interventions
- Other: Treatment for clinical practise
- First Posted Date
- 2018-06-11
- Last Posted Date
- 2022-08-26
- Lead Sponsor
- Fondazione Italiana Linfomi - ETS
- Target Recruit Count
- 400
- Registration Number
- NCT03552003
- Locations
- 🇮🇹
Azienda Ospedaliera S. Giuseppe Moscati - S.C. Ematologia e Trapianto emopoietico, Avellino, Italy
🇮🇹Centro Riferimento Oncologico - S.O.C. Oncologia Medica A, Aviano, Italy
🇮🇹Azienda Ospedaliera di Cosenza - UOC Ematologia, Cosenza, Italy
Study on the Role of FDG-PET in Patients With FL at Time of Relapse/Progression
- Conditions
- Follicular Lymphoma
- First Posted Date
- 2018-05-16
- Last Posted Date
- 2020-02-06
- Lead Sponsor
- Fondazione Italiana Linfomi - ETS
- Target Recruit Count
- 175
- Registration Number
- NCT03525665
- Locations
- 🇮🇹
Università Cattolica del Sacro Cuore - Policlinico "A. Gemelli", Roma, RM, Italy
🇮🇹SOS Ematologia Ospedale C. Massaia, Asti, Italy
🇮🇹A.O. Spedali Civili di Brescia - Ematologia, Brescia, Italy
Non-invasive Diagnostics and Monitoring of MRD and Clonal Evolution in Waldenström's Macroglobulinemia and in IgM-MGUS
- Conditions
- Waldenstrom Macroglobulinemia
- Interventions
- Other: MRD and clonal evolution
- First Posted Date
- 2018-05-11
- Last Posted Date
- 2024-06-21
- Lead Sponsor
- Fondazione Italiana Linfomi - ETS
- Target Recruit Count
- 300
- Registration Number
- NCT03521596
- Locations
- 🇮🇹
SOS Ematologia Ospedale C. Massaia, Asti, Italy
🇮🇹Divisione di Ematologia Ospedale Niguarda, Milano, MI, Italy
🇮🇹A.O. Universitaria Di Parma, Parma, Italy
R-CHOP14 or R-CHOP21 &Consolidation PET-Oriented Radiotherapy (RT) in DLBCL Patients
- Conditions
- Diffuse Large B Cell Lymphoma
- Interventions
- Drug: Treatment plan
- First Posted Date
- 2017-12-06
- Last Posted Date
- 2022-03-03
- Lead Sponsor
- Fondazione Italiana Linfomi - ETS
- Target Recruit Count
- 109
- Registration Number
- NCT03364439
- Locations
- 🇮🇹
Ospedale di Castelfranco Veneto - Ematologia, Castelfranco Veneto, Italy
🇮🇹A.O. SS. Antonio e Biagio e C. Arrigo, Alessandria, Italy
🇮🇹Ospedale Businco, Cagliari, Italy
FIL Study on ABVD DD-DI As Upfront Therapy in HL.
- Conditions
- Hodgkin Lymphoma
- Interventions
- First Posted Date
- 2017-05-19
- Last Posted Date
- 2024-12-31
- Lead Sponsor
- Fondazione Italiana Linfomi - ETS
- Target Recruit Count
- 500
- Registration Number
- NCT03159897
- Locations
- 🇮🇹
Ospedale Madonna delle Grazie - Ematologia, Matera, Italy
🇮🇹Presidio ospedaliero "A. TORTORA", Pagani, Italy
🇮🇹Istituto Clinico Humanitas - U.O. Ematologia, Rozzano (MI), Italy
Metronomic Chemotherapy in Elderly Non-fit Patients With Aggressive B-Cell Lymphomas
- Conditions
- Aggressive Non-Hodgkin Lymphoma
- Interventions
- First Posted Date
- 2017-05-19
- Last Posted Date
- 2021-12-20
- Lead Sponsor
- Fondazione Italiana Linfomi - ETS
- Target Recruit Count
- 21
- Registration Number
- NCT03161054
- Locations
- 🇮🇹
A.O. Spedali Civili di Brescia - Ematologia, Brescia, Italy
🇮🇹Ospedale di Castelfranco Veneto - Ematologia, Castelfranco Veneto, Italy
🇮🇹Azienda Ospedaliera Arcispedale Santa Maria Nuova - IRCCS c/o CORE (II piano) - Ematologia, Reggio Emilia, Italy